Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating
Source: SeekingAlpha
2025-12-04 17:07:18 ET
Read the full article on Seeking Alpha
For further details see:
Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating
Stoke Therapeutics Inc.
NASDAQ: STOK
STOK Trading
-4.73% G/L:
$37.63 Last:
163,581 Volume:
$37.30 Open:
STOK Latest News
March 04, 2026 05:06:00 pm
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
February 24, 2026 04:01:00 pm
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 11, 2026 07:30:00 am
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
February 04, 2026 04:01:00 pm
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
STOK Stock Data
$1,859,163,232
44,494,260
1.78%
51
N/A
Biotechnology & Life Sciences
Healthcare
US
Bedford
